Observational study to assess quality of life in patients with pancreatic neuroendocrine tumours receiving treatment with Everolimus: The OBLIQUE Study (UK Phase IV trial)

Conclusions: The OBLIQUE study demonstrates that HRQoL is maintained in patients with PanNENs during treatment with everolimus in a UK real-world setting. This study adds to the limited HRQoL data available in this patient group.
Source: Neuroendocrinology - Category: Endocrinology Source Type: research